Extended Stay America, Inc. (STAY) continued its downward trend with the stock declining -1.07% or $-0.17 to close the day at $15.77 on active trading volume of 2.2M shares, compared to its three month average trading volume of 1.08M. The Charlotte North Carolina 28277 based company has been outperforming the lodging group over the past 52 weeks, with the stock gaining 12.9%, compared to the industry which has advanced 9.97% over the same period. With RSI of 45.98, the stock should still continue to rise and get closer to its one year target estimate of $18.27, making it a hold for now.
Extended Stay America, Inc. develops, owns, and operates hotels in the United States and Canada. As of December 31, 2015, the company had 629 hotels with approximately 69,400 consisting of 626 hotels with approximately 68,900 rooms under the Extended Stay America brand; and 3 hotels with 500 rooms under the Extended Stay Canada brand. It serves customers in the mid-priced extended stay segment. Extended Stay America, Inc. was founded in 1995 and is headquartered in Charlotte, North Carolina.
Deere & Company (DE) retreated with the stock falling -1.22% or $-1.3 to close at $105.19 on light trading volume of 2.2M compared its three months average trading volume of 3.15M. The Moline Illinois 61265 based company operating under the Farm & Construction Machinery industry has been trending up for the last 52 weeks, with the shares price now 46.66% up for the period and up by 2.09% so far this year. With price target of $101.35 and a 54.19% rebound from 52-week low, Deere & Company has plenty of upside potential, making it a hold with a view buy.
Deere & Company, together with its subsidiaries, manufactures and distributes agriculture and turf, and construction and forestry equipment worldwide. The companys Agriculture and Turf segment provides agriculture and turf equipment, and related service parts, including large, medium, and utility tractors; loaders; combines, cotton pickers and strippers, and sugarcane harvesters; related front-end harvesting equipment; sugarcane loaders and pull-behind scrapers; and tillage, seeding, and application equipment, including sprayers, nutrient management, and soil preparation machinery. This segment also provides hay and forage equipment comprising self-propelled forage harvesters and attachments, balers, and mowers; turf and utility equipment, including riding lawn equipment and walk-behind mowers, golf course equipment, utility vehicles, and commercial mowing equipment, as well as associated implements; integrated agricultural management systems technology and solutions; and other outdoor power products. Its Construction and Forestry segment provides backhoe loaders; crawler dozers and loaders; four-wheel-drive loaders; excavators; motor graders; articulated dump trucks; landscape loaders; skid-steer loaders; and log skidders, feller bunchers, log loaders, log forwarders, log harvesters, and related attachments that are used in construction, earthmoving, material handling, and timber harvesting applications. The companys Financial Services segment finances sales and leases of new and used agriculture and turf equipment, and construction and forestry equipment. This segment also provides wholesale financing to dealers of the foregoing equipment; finances retail revolving charge accounts; and offers extended equipment warranties. The company markets its products primarily through independent retail dealer networks and retail outlets. Deere & Company was founded in 1837 and is headquartered in Moline, Illinois.
Agios Pharmaceuticals, Inc. (AGIO) failed to extend gains with the stock declining -9.94% or $-4.72 to close the day at $42.78 on lower than average trading volume of 2.19M shares, compared to its three month average trading volume of 815.53K. The Cambridge Massachusetts 02139 based company has been outperforming the biotechnology companies by -18.8852% for last three months and its recent losses have trimmed gains to 2.52% YTD, versus the biotechnology industry which is up 3.69% for the same period. The RSI of 41.69 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The companys product candidates include AG-221, an potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II, Phase Ib combination, and Phase III IDHENTIFY clinical trials for the treatment of hematologic malignancies, as well as is in Phase 1/2 clinical trial for treating solid tumors, including AITL. Its product candidates also comprise AG-120, an potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical and Phase Ib combination clinical trials for the treatment of hematologic malignancies, as well as Phase I clinical trial for treating solid tumors; and AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors. In addition, the company is involved in developing AG-348, an potent activator that is in Phase II DRIVE PK clinical trial; and AG-519 potent activator that are in Phase I clinical trial for treating patients with pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; Celgene International II Sarl to develop and commercialize AG-881 products; and Abbott and Celgene Corp. to develop and commercialize companion diagnostic tests on Abbott’s m2000 RealTime System. The company was founded in 2007 and is based in Cambridge, Massachusetts.